Background-It has been suggested that intracellular Ca 2ϩ overload in cardiac myocytes leads to the development of diabetic cardiomyopathy. Troglitazone, an insulin-sensitizing agent, is a promising therapeutic agent for diabetes and has been shown to prevent diabetes-induced myocardial changes. To elucidate the underlying mechanism of troglitazone action on cardiac myocytes, the effects of troglitazone on voltage-dependent Ca 2ϩ currents were examined and compared with classic Ca 2ϩ antagonists (verapamil and nifedipine). 
M yocardial contractile dysfunction is a major complication of diabetes, known as diabetic cardiomyopathy. [1] [2] [3] [4] The subcellular mechanisms responsible for cardiomyopathy are unknown. However, several cellular defects, including depressions in sarcoplasmic reticular Ca 2ϩ uptake, 5 Na ϩ -K ϩ pump, 6 sarcolemmal Ca 2ϩ pump, Na ϩ -Ca 2ϩ exchanger activities, 7 and the alteration of mitochondrial functions, 8 have been suggested to be contributors to the development of this disease. The net result of these changes in Ca 2ϩ homeostasis causes an intracellular Ca 2ϩ overload, thereby resulting in cellular damage and, ultimately, diabetic cardiomyopathy. Moreover, diabetes prolongs the action potential duration 9 -12 and increases the number of myocardial voltage-dependent Ca 2ϩ channels, 13, 14 something that may also play a role in causing diabetic cardiomyopathy. In fact, it has been reported that in chronically diabetic rats, elevated tissue Ca 2ϩ levels are present 15 and treatment with verapamil or diltiazem, a voltage-dependent L-type Ca 2ϩ channel blocker, lessens cardiac dysfunction. 16 -18 Thus, it is likely that excess Ca 2ϩ influx through the voltage-dependent Ca 2ϩ channels contributes to induce intracellular Ca 2ϩ overload and consequently diabetic cardiomyopathy.
Troglitazone, a novel member of the insulin-sensitizing thiazolidinediones, has been widely used to treat patients with non-insulin-dependent diabetes mellitus and other insulinresistant diseases. Treatment with troglitazone reduced hyperglycemia, plasma triglycerides, and blood pressure. 19 -22 Recent studies show that troglitazone attenuates highglucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes 23 and may improve cardiac function in diabetic patients. 24 Until now, the mechanisms underlying the beneficial effects of troglitazone on hearts have not been clearly established, but several articles have shown that troglitazone inhibits the voltage-dependent L-type Ca 2ϩ currents (I Ca,L ) in vascular smooth muscle cells. 25, 26 Therefore, the purpose of the present study was to clarify the effects of troglitazone on the voltage-dependent Ca 2ϩ currents (T-type [I Ca,T ] and L-type) in cardiac myocytes. We have also made comparisons with the classic Ca 2ϩ antagonists verapamil and nifedipine.
Methods

Cell Preparation
Single atrial myocytes were obtained from guinea pig hearts by an enzymatic dissociation procedure described elsewhere. 27 Briefly, the animals were anesthetized with sodium pentobarbital, and their hearts were rapidly removed and retrogradely Langendorff-perfused at 35°C to 37°C with an oxygenated Tyrode's solution. The hearts were then perfused with Ca 2ϩ -free Tyrode's solution for Ϸ10 minutes and subsequently with the same solution containing collagenase (0.04% wt/vol type 1, Sigma Chemical Co) for 17 to 20 minutes. The digested hearts were stored in a high-K ϩ /low-Cl Ϫ solution 27 at 5°C for later experimentation. The atria were then removed, and cells were obtained by gentle mechanical agitation. This procedure consistently yielded an acceptable number of quiescent and relaxed atrial cells.
Solution and Drugs
The composition of the normal Tyrode's solution was (in mmol/L) NaCl 136.5, KCl 5.4, CaCl 2 1.8, MgCl 2 0.53, glucose 5.5, and HEPES-NaOH buffer 5, pH 7.4. The Ca 2ϩ -free Tyrode's solution was identical to normal Tyrode's solution except that CaCl 2 was omitted. To record voltage-dependent Ca 2ϩ currents, K ϩ currents were eliminated by the internal Cs and external Ba (5 mmol/L), and Ca 2ϩ -activated currents were blocked by 10 mmol/L EGTA and 2 mmol/L BAPTA in the internal solution. The composition of the internal solution was (in mmol/L) CsCl 140, EGTA 10, BAPTA 2, Na 2 -ATP 3, GTP (sodium salt, Sigma) 0.1, MgCl 2 1, and HEPESCsOH buffer 5, pH 7.3. In the experiments in which the cells were held at Ϫ80 mV, the bath was perfused with the following solution (in mmol/L) to block the voltage-dependent Na ϩ current: tetraethylammonium chloride (TEA-Cl) 140, BaCl 2 5, MgCl 2 0.53, glucose 5.5, tetrodotoxin (TTX) 0.01, and HEPES-CsOH buffer 5, pH 7.4. Troglitazone was obtained from Sankyo Co Ltd. Troglitazone was dissolved in DMSO to give a stock solution of 1 to 30 mmol/L, and the final concentration of DMSO applied to the bathing solution was 0.1%. Nifedipine and verapamil were dissolved in ethanol to give a stock solution of 10 mmol/L. In several experiments, cAMP was added to the pipette solution. (Ϯ)Isoproterenol, cAMP, verapamil, and nifedipine were purchased from Sigma.
Recording Technique and Data Analysis
Membrane currents were recorded with patch electrodes in a wholecell clamp configuration 27, 28 and a patch-clamp amplifier (EPC-7, List Electronics). The heat-polished patch electrodes had a tip resistance of 3 to 6 M⍀. The membrane currents were monitored with a high-gain storage oscilloscope (COS 5020-ST, Kikusui Electronics). At the start of each experiment, the series resistance was compensated. The data were stored on video cassettes with a PCM converter system (RP-880, NF electronic circuit design). Later, the data were reproduced, low-pass-filtered at 2 kHz (Ϫ3 dB) with a Bessel filter (FV-665, NF, 48-dB/octave slope attenuation), sampled at 5 kHz, and analyzed off-line on a computer with p-Clamp software (Axon Instruments). In general, we used a holding potential of Ϫ40 mV at a frequency of 0.2 Hz to inactivate the voltagedependent Na ϩ current. In experiments to evaluate the contribution of I Ca,T or voltage-dependence of the drug, a holding potential of Ϫ80 mV was used in combination with the high-TEA solution containing Ba 2ϩ 5 mmol/L in place of Ca 2ϩ (see Methods). Statistical results are expressed as meanϮSD. Student's t tests were performed, with a value of PϽ0.05 considered significant. The first data were usually taken after the current amplitude of Ca 2ϩ currents had been stabilized (2 to 3 minutes after the rupture of the membrane). After that, we could investigate the effects of drugs on the voltage-dependent Ca 2ϩ currents for Ϸ15 to 20 minutes. In experiments with cAMP, data were taken immediately after the rupture of the membrane. To measure the amplitude of the voltagedependent Ca 2ϩ currents, we subtracted from the peak amplitude of Ca 2ϩ currents in the original trace to the current level in the presence of Cd 2ϩ (1 mmol/L). In preliminary experiments, we confirmed that 0.1% DMSO did not affect the voltage-dependent Ca 2ϩ currents significantly. Furthermore, to exclude the effects of DMSO, 0.1% DMSO was always added to the bathing solution. The steady-state inactivation parameters of the voltage-dependent Ca 2ϩ currents were analyzed with double-pulse protocols. Conditioning voltage pulses (3 seconds in duration) for various membrane potentials between Ϫ70 and ϩ0 mV were applied from a holding potential of Ϫ80 mV. Ten milliseconds after the end of each conditioning pulse, a test pulse of ϩ10 mV (0.2 seconds in duration) was applied to elicit Ca 2ϩ currents. The ratio between the amplitude of the Ca 2ϩ currents with conditioning pulse and that without conditioning pulse was plotted for the membrane potential of each conditioning pulse. The interval between sets of double pulses was 20 seconds.
Results
Effects of Troglitazone on Voltage-Dependent I Ca,L
The effects of troglitazone on the voltage-dependent I Ca,L were examined in single atrial myocytes (Figure 1 ). The membrane potential was held at Ϫ40 mV, and command voltage pulses (320 ms in duration) to ϩ0 mV were applied at 0.2 Hz. In control cells, a transient inward current was elicited during each voltage pulse ( Figure 1A, a) . The inward current was Immediately after application of isoproterenol, there was a rapid small increase in I Ca,L , probably reflected by direct activation of the GTP-binding proteins (G s ), 29 and then a large increase in I Ca,L was observed. The additional application of troglitazone 30 mol/L completely abolished I Ca,L (Figure 4 , c). Moreover, when cAMP was applied through the patch pipette, I Ca,L increased from Ϫ370 to Ϫ1080 pA in this cell ( Figure 5A and 5B). The existence of 2 distinct Ca 2ϩ currents has been shown for cardiac myocytes in several kinds of mammalian hearts. 30 . Sodium removal induced cell contracture, but under our conditions with EGTA 10 mmol/L and BAPTA 2 mmol/L in the patch pipette, the cell attached to the patch electrode survives, probably owing to the diffusion of EGTA and BAPTA into the cytosol. The cells were held at Ϫ40 or Ϫ80 mV ( Figure 6A ), and command voltage steps (320 ms in duration) were applied to various membrane potentials. The current-voltage relationships of the peak inward current are shown in Figure 6C . At a holding potential of Ϫ40 mV, the inward current was elicited at positive potentials to Ϫ30 mV ( Figure 6A, right) . A small fraction of current was inactivated at the command pulses to Ϫ20 and Ϫ10 mV. Conversely, when the cell was held at Ϫ80 mV, the transient inward current was recorded at a command potential of Ϫ30 mV and was overlapped on the noninactivated component at a command potential of Ϫ20 mV ( Figure 6A, left) . The current traces subtracted from the current of a holding potential of Ϫ80 mV to that of a holding potential of Ϫ40 mV at command potentials of Ϫ30, Ϫ20, and ϩ0 mV are shown in Figure 6B . The transient inward current rapidly inactivated within 50 ms and could be discriminated from the sustained component. currents exist in guinea pig atrial myocytes. The fast inward current consisted of I Ca,T , and the slow component consisted primarily of I Ca,L . Figure 7 shows the effects of troglitazone on both types of Ca 2ϩ currents. I Ca,T and I Ca,L were elicited at a command voltage to Ϫ30 and ϩ10 mV from a holding potential of Ϫ80 mV, respectively. Troglitazone 10 mol/L inhibited both types of Ca 2ϩ currents ( Figure 7A and 7B) but inhibited I Ca,L more effectively than I Ca,T ( Figure 7B ). Figure 8 shows the effects of troglitazone on the inactivation time courses of I Ca,L . Under conditions in which the cell was perfused with normal Tyrode's solution, the inactivation time courses of I Ca,L were well fitted by the sum of 2 exponentials ( Figure 8A and Table) as previously described. 34 Troglitazone 10 mol/L did not affect the time courses of inactivation of I Ca,L significantly (Figure 8 and Table) . The differences between the values of 1 and 2 in the control and those in the presence of troglitazone were not statistically significant.
Effects of Troglitazone on the Kinetic Parameters of the Voltage-Dependent I Ca,L
The use-dependent block of troglitazone was also examined and compared with the classic Ca 2ϩ antagonists verapamil and nifedipine as shown in Figure 9 . The changes in the amplitude of I Ca,L elicited by successively applied command pulses were measured in the absence or presence of each drug with a test depolarizing pulse to ϩ0 mV from a holding potential of Ϫ40 mV at 0.2 Hz. The amplitude of I Ca,L recorded by the last pulse of a train stimulation before application of the agents ( Figure 9A through D) was normalized to 1.0. In control conditions (Figure 9A ), the amplitude of I Ca,L elicited by the first command pulse (b) was not inhibited and remained nearly constant during the successive repetitive pulses (c). The small decrease of the current (8Ϯ3% of the first pulse, nϭ5) during 1-minute application of repetitive stimulation was thought to be induced simply by Ca 2ϩ channel rundown. Verapamil (1 mol/L, Figure 9B) produced very little inhibition of Ca 2ϩ current in the absence of test pulses (b), but blockade increased with repeated depolarizations (c). Conversely, in studies with the same pulse protocol, nifedipine blockade was different ( Figure 9C ). The first current after the quiescent period gave a good estimate of the final level of blockade (b and c). Figure 9D shows the use-dependent effects of troglitazone 10 mol/L. As in the case of nifedipine, the inward current elicited by the first command pulse after a 2-minute quiescent period was consistently inhibited by 63Ϯ10% (nϭ5, PϽ0.01), which was different from that recorded with verapamil. With the repetitive stimulations, the inward current decreased slightly, by 13Ϯ7% (nϭ5) from the first pulse during repetitive stimulation ( Figure 9D, b) , but could not discriminate the simple rundown of the Ca 2ϩ channel. These results suggest that troglitazone inhibited I Ca,L mainly in a use-independent manner.
Effects of Troglitazone on the Time Courses of Inactivation of the Voltage-Dependent I Ca.L in Atrial Myocytes
The influence of the holding potential on the inhibitory effects of nifedipine and troglitazone was compared as shown in Figure 10 . In these experiments, the command voltage steps (320 ms in duration) to ϩ10 mV from a holding potential of Ϫ40 or Ϫ80 mV, where the voltage-dependent Ca 2ϩ currents consisted primarily of I Ca,L , were applied. The peak amplitude of I Ca,L in the absence of drugs was normalized to 100. The percentage inhibition induced by nifedipine and troglitazone is shown in Figure 10B . Nifedipine 1 mol/L reduced the amplitude of I Ca,L by 96Ϯ4% at a holding potential of Ϫ40 mV, whereas it inhibited it by only 34Ϯ8% at a holding potential of Ϫ80 mV. Conversely, troglitazone 10 mol/L inhibited I Ca,L by Ϸ70% at each membrane potential. Furthermore, the effects of troglitazone and nifedipine on the voltage-dependent availability of L-type Ca 2ϩ channels were examined by means of doublepulse protocols (Figure 11 ). The test pulse to ϩ10 mV from a holding potential of Ϫ80 mV was preceded by a 3-second conditioning pulse to various membrane potentials. The relationships between membrane potentials and the f ϱ value in the absence and presence of the drug were fitted by the following Boltzmann equation using the least-squares method: f ϱ (V)ϭf ϱmax /{1ϩexp[(VϪa)/b]}, where f ϱmax is the maximal value of f ϱ (in control conditions, the value of f ϱmax ϭ1), V is membrane potential in mV, a is membrane potential at 1/2 f ϱmax , and b is slope factor. In the absence of the drug, f ϱmax ϭ1, aϭϪ21.2 mV, and bϭ5.13 mV. In the presence of nifedipine 1 mol/L, f ϱmax ϭ0.68, aϭϪ37.0 mV, and bϭ6.6 mV ( Figure 11A) . Thus, nifedipine decreased the maximal Ca 2ϩ channel availability (0.69Ϯ0.05 of the control, nϭ5), with a significant shift of the curve toward the negative (Ϫ18Ϯ4 mV, nϭ5). Conversely, in the absence of troglitazone 10 mol/L, f ϱmax ϭ1, aϭϪ21.3 mV, and bϭ5.33 mV. In the presence of troglitazone, f ϱmax ϭ0.39, aϭϪ22.3 mV, and bϭ6.0 mV ( Figure 11B ). Thus, troglitazone reduced the maximal Ca 2ϩ channel availability (0.36Ϯ0.1 of control, nϭ5) but did not show any significant shift of the voltagedependent inactivation curve (Ϫ23.4Ϯ3.4 mV in the control versus Ϫ25.9Ϯ5.0 mV in the presence of troglitazone, nϭ5, PϭNS).
Discussion
We have demonstrated here that troglitazone had inhibitory effects on voltage-dependent Ca 2ϩ currents in single atrial myocytes from the guinea pig. The inward Ba 2ϩ current in place of Ca 2ϩ could easily be divided into 2 components with distinct physiological properties, as described in mammalian cardiac myocytes. 30 -33 One component had characteristics identical to the I Ca,L , including slow inactivation ( Figure 6 ) and sensitivity to dihydropyridine (Figures 9 and 10 ) and isoproterenol ( Figure 4) . The second component, I Ca,T , had a fast inactivation (Figures 6 and 7 ) and small amplitude (ϷϪ100 pA) even in the presence of Ba 2ϩ and insensitivity to dihydropyridine (nifedipine 1 mol/L) and isoproterenol (data not shown). We found that troglitazone inhibited both types of voltage-dependent Ca 2ϩ currents in atrial myocytes, although it inhibited I Ca,L more effectively than I Ca,T . channel blockers such as verapamil and diltiazem prevent the development of diabetic cardiomyopathy. 16 -18 These cardioprotective effects of Ca 2ϩ -blocking drugs have also been reported in Syrian cardiomyopathic hamsters 36 and in patients with hypertrophic cardiomyopathy. 37 Therefore, the mode of action of troglitazone on I Ca,L was compared with that of the classic Ca 2ϩ antagonists verapamil and nifedipine. As shown in Figures 10 and 11 , troglitazone reduced I Ca,L but did not cause a significant shift in the steady-state inactivation curve. Conversely, nifedipine, a dihydropyridine Ca 2ϩ antagonist, which has a high affinity for the inactivated state of the channel but much less affinity for other states (eg, closed, open), showed strong voltage-dependent effects and caused a distinct negative shift of the steady-state inactivation curve. Thus, it is unlikely that troglitazone inhibits I Ca,L by preferentially binding the inactivated states of the channels. Also, troglitazone did not exhibit significant use-dependent characteristics, which was different from verapamil ( Figure 9 ), as previously described. 38 Potencies of the use-dependent inhibition might be closely related to the ionization constants of the drug as shown by Sanguinetti and Kass. 39 According to this model, charged forms of the drug can reach their receptors inside the channel by a hydrophilic pathway available only when the channel gates are open and hence are characterized by a significant use-dependent block. In con- trast, an uncharged form of the drug easily reaches its receptors via a hydrophobic region of the membrane without channel opening and thereby does not show significant use-dependent effects. Verapamil (pK a ϭ8.7) is almost entirely in the charged form at pH 7.4, whereas troglitazone (pK a ϭ6.1) 40 exists almost entirely in the neutral form at the same pH. Thus, opening of the channels may not be necessary for troglitazone to affect I Ca,L , as shown in Figure 9 . Furthermore, the time courses of Ca 2ϩ current decay were little affected by troglitazone. From these observations, troglitazone did not appear to inhibit the Ca 2ϩ channels by binding to activated Ca 2ϩ channels. Thus, the mechanisms by which troglitazone affects the voltage-dependent Ca 2ϩ channels are unknown at present, but troglitazone may interact with L-type Ca 2ϩ channels in a manner distinct from the classic Ca 2ϩ
antagonists. 41 The present study indicates that troglitazone inhibited the voltage-dependent Ca 2ϩ currents (I Ca,L and I Ca,T ) in cardiac myocytes in therapeutic concentrations. Under normal circumstances, the current through the T-type Ca 2ϩ channel is unlikely to be very important in atrial and ventricular myocytes, because in a well-polarized cell, such as atrial and ventricular cells, Na current is much larger and activates in a similar voltage range. Also, because L-type Ca 2ϩ channels inactivate more slowly, they are likely to be more important than T-type channels. However, T-type Ca 2ϩ channels may contribute to the generation of pacemaker activities in pacemaker cells 42 and may make hypertrophied ventricular myocytes more prone to spontaneous action potentials and increase the likelihood of arrhythmia in partially depolarized hypertrophied myocardium. 43 Troglitazone may affect the electrical activities under these conditions by inhibiting I Ca,T . Conversely, troglitazone inhibited I Ca,L more effectively than I Ca,T . The inhibitory effects of troglitazone on I Ca,L did not show significant voltage-and use-dependent properties as observed in classic Ca 2ϩ antagonists. 38 From these unique actions, troglitazone may inhibit cardiac Ca 2ϩ channels in a similar way in well-polarized cells as well as in partially depolarized cells. Also, it may antagonize the effects of isoproterenol on I Ca,L . Several studies have shown that in diabetic animals, the duration of action potential in cardiac myocytes is markedly longer, whereas the resting membrane potential is not altered. 9 -12 In addition, an augmented number of Ca 2ϩ antagonist receptor binding sites and an increase of voltage-dependent L-type Ca 2ϩ channels have been reported in diabetic hearts. 13, 14 The increased influx of Ca 2ϩ through the voltage-dependent Ca 2ϩ channels may cause Ca 2ϩ overload, which appears to be linked to the cardiac pathology in diabetic cardiomyopathy. 16 -18 The present study shows that troglitazone inhibits voltage-dependent Ca 2ϩ currents (I Ca,T and I Ca,L ) and then antagonizes the effects of isoproterenol in cardiac myocytes, which may play a role in preventing diabetes-induced intracellular Ca 2ϩ overload and then myocardial changes. In fact, recent studies have shown that troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes 23 and improves cardiac function in diabetes mellitus. 24 From these observations, troglitazone may be a unique agent for diabetic cardiomyopathy, but further studies are needed to clarify this possibility in diabetic patients.
